Quick Answer
LIPELLA PHARMACEUTICALS INC. reported Operating Income Loss of -$5.08 million for the year ending 2024.
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -7.0% in Operating Income Loss from 2023 to 2024.
- This data is from LIPELLA PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 28, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$736.7 thousand | Q2 2022: -$781.1 thousand | Q3 2022: -$712.6 thousand | Q1 2023: -$1.08 million | Q2 2023: -$1.58 million | Q3 2023: -$1.36 million | Q1 2024: -$1.22 million | Q2 2024: -$952.2 thousand | Q3 2024: -$1.46 million | Q1 2025: -$1.33 million | Q2 2025: -$1.36 million | Q3 2025: -$1.27 million.
- Over the full 4 years of available data (2021 to 2024), LIPELLA PHARMACEUTICALS INC.'s Operating Income Loss has declined by 165.2%.
- Historical annual values: Fiscal year 2024: -$5.08 million | Fiscal year 2023: -$4.75 million | Fiscal year 2022: -$2.59 million | Fiscal year 2021: -$1.92 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: